Duldulao et al. in 2013 carried out TP53 and KRAS genotyping in rectal cancer and presented that tumors with the KRAS mutation had a lower possibility to achieve pCR than those with wild-type KRAS. The gene discussed is KRAS; the disease is rectal cancer.